<Anchor> The
current vaccine supply and demand situation is not good. The introduction of the Moderna vaccine, which was scheduled to enter the country at the end of this month, has been delayed to next month, and the Novavax vaccine has not yet been approved.
This is Yoo Seung-hyun, medical reporter.
<Reporter> This
is Hyundai Motor Research Center in Hwaseong, Gyeonggi-do.
Employees and subcontractors received Pfizer vaccines from in-house medical staff.
In-house inoculation targets at worksites are 43 domestic locations and about 303,000 people.
Most of the 50's vaccines have also been switched from Moderna to Pfizer.
This is due to supply disruptions in Moderna vaccines.
The government said on the 23rd that Moderna had been told that "the vaccine for Korea, which will leave on the 25th, could not be loaded on the ship," and that "the amount in July will be supplied in August."
Many of Moderna's vaccines are produced in Switzerland and bottled in Spain.
The government explained that there will be no problems with the introduction of the Moderna vaccine, which will be introduced in August, because it is produced in non-European countries.
The timing of consignment production of some of Moderna vaccines in Korea is also being delayed.
As the prototype is expected to be released in late August or early September, the actual inoculation may be delayed.
The Novavax vaccine, which is scheduled to be introduced in 40 million doses, has not even started the domestic and international approval process.
The quarantine authorities were confident that there would be no problems until the 50s and 18-49-year-olds if vaccines from Pfizer, Janssen, and Moderna arrive as scheduled after August.